152 related articles for article (PubMed ID: 32516101)
21. Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America.
Alvarez C; Salazar R; Galindez J; Rangel F; Castaãeda ML; Lopardo G; Cuhna CA; Roldan Y; Sussman O; Gutierrez G; Cure-Bolt N; Seas C; Carcamo C; Castrillo M
Braz J Infect Dis; 2010; 14(3):256-63. PubMed ID: 20835509
[TBL] [Abstract][Full Text] [Related]
22. An observational study of the prevalence of metabolic syndrome in treatment-experienced people living with HIV in Singapore.
Ang LW; Ng OT; Boudville IC; Leo YS; Wong CS
PLoS One; 2021; 16(6):e0252320. PubMed ID: 34077481
[TBL] [Abstract][Full Text] [Related]
23. [Safety study of 52-week highly active antiretroviral therapy in 198 HIV/AIDS Chinese patients].
Li WJ; Dai Y; Han Y; Qiu ZF; Xie J; Zuo LY; Li YL; Li TS
Zhonghua Yi Xue Za Zhi; 2011 May; 91(19):1318-22. PubMed ID: 21756757
[TBL] [Abstract][Full Text] [Related]
24. Insulin resistance in the HIV-infected population: the potential role of mitochondrial dysfunction.
Shikuma CM; Day LJ; Gerschenson M
Curr Drug Targets Infect Disord; 2005 Sep; 5(3):255-62. PubMed ID: 16181144
[TBL] [Abstract][Full Text] [Related]
25. Targets of metabolic toxicity of HIV antiretroviral drugs: the multiple roads to lipodystrophy and metabolic syndrome.
Domingo P; Villarroya F
Curr Pharm Des; 2010 Oct; 16(30):3337-8. PubMed ID: 20687885
[No Abstract] [Full Text] [Related]
26. The human immunodeficiency virus and the cardiometabolic syndrome in the developing world: an African perspective.
Mutimura E; Crowther NJ; Stewart A; Cade WT
J Cardiometab Syndr; 2008; 3(2):106-10. PubMed ID: 18453811
[TBL] [Abstract][Full Text] [Related]
27. [Hypertension and metabolic syndrome in HIV infected patients].
Zanuzzi MG; Cattaneo MJ; López SM; Pérez Maure MLÁ; Romero CA
Medicina (B Aires); 2020; 80(5):453-461. PubMed ID: 33048789
[TBL] [Abstract][Full Text] [Related]
28. Features of Metabolic Syndrome and Its Associated Factors during Highly Active Antiretroviral Therapy in Ouagadougou (Burkina Faso).
Guira O; Tiéno H; Diendéré AE; Sagna Y; Diallo I; Yaméogo B; Zoungrana L; Yaméogo TM; Bognounou R; Drabo JY
J Int Assoc Provid AIDS Care; 2016; 15(2):159-63. PubMed ID: 26307211
[TBL] [Abstract][Full Text] [Related]
29. Human immunodeficiency virus in an aging population, a complication of success.
Kirk JB; Goetz MB
J Am Geriatr Soc; 2009 Nov; 57(11):2129-38. PubMed ID: 19793157
[TBL] [Abstract][Full Text] [Related]
30. Independent predictors of metabolic syndrome in HIV-infected patients.
Alencastro PR; Fuchs SC; Wolff FH; Ikeda ML; Brandão AB; Barcellos NT
AIDS Patient Care STDS; 2011 Nov; 25(11):627-34. PubMed ID: 21936688
[TBL] [Abstract][Full Text] [Related]
31. Prevalence and risk factors of poor immune recovery among adult HIV patients attending care and treatment centre in northwestern Tanzania following the use of highly active antiretroviral therapy: a retrospective study.
Gunda DW; Kilonzo SB; Kamugisha E; Rauya EZ; Mpondo BC
BMC Res Notes; 2017 Jun; 10(1):197. PubMed ID: 28595630
[TBL] [Abstract][Full Text] [Related]
32. Emerging manifestations of HIV/AIDS: is it the virus or the antiviral therapy?
Laurence J
AIDS Read; 2001 Feb; 11(2):64-5. PubMed ID: 11279873
[No Abstract] [Full Text] [Related]
33. [AIDS--past, present and future].
Levy I; Shasha D; Grossman Z
Harefuah; 2011 Mar; 150(3):246-50, 304, 303. PubMed ID: 21574358
[TBL] [Abstract][Full Text] [Related]
34. Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients.
Palacios R; Santos J; García A; Castells E; González M; Ruiz J; Márquez M
HIV Med; 2006 Jan; 7(1):10-5. PubMed ID: 16313287
[TBL] [Abstract][Full Text] [Related]
35. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
[TBL] [Abstract][Full Text] [Related]
36. Metabolic syndrome in French HIV-infected patients: prevalence and predictive factors after 3 years of antiretroviral therapy.
Biron A; Bobin-Dubigeon C; Volteau C; Piroth L; Perré P; Leport C; Prazuck T; Jovelin T; Billard M; Sébille V; Bard JM; Raffi F; Biron C
AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1672-8. PubMed ID: 22731114
[TBL] [Abstract][Full Text] [Related]
37. Association of HIV infection with metabolic syndrome among normal or underweight young adults: evidence from the CHART cohort.
Shi R; Chen X; Lin H; Shen W; Xu X; Zhu B; Xu X; Ding Y; Wong FY; He N
Biosci Trends; 2021 Jan; 14(6):450-456. PubMed ID: 33328394
[TBL] [Abstract][Full Text] [Related]
38. [Metabolic syndrome in HIV-infected patients with favorable response to antiretroviral therapy].
Prisicăriu LJ; Dorobat CM; Manciuc C; Nicolau IC
Rev Med Chir Soc Med Nat Iasi; 2011; 115(3):776-80. PubMed ID: 22046786
[TBL] [Abstract][Full Text] [Related]
39. Highly active antiretroviral therapy and dyslipidemia in people living with HIV/AIDS in Fako Division, South West Region of Cameroon.
Nsagha DS; Weledji EP; Assob NJ; Njunda LA; Tanue EA; Kibu OD; Ayima CW; Ngowe MN
BMC Cardiovasc Disord; 2015 Aug; 15():95. PubMed ID: 26315756
[TBL] [Abstract][Full Text] [Related]
40. Metabolic syndrome in patients on first-line antiretroviral therapy containing zidovudine or tenofovir in rural Lesotho, Southern Africa.
Labhardt ND; Müller UF; Ringera I; Ehmer J; Motlatsi MM; Pfeiffer K; Hobbins MA; Muhairwe JA; Muser J; Hatz C
Trop Med Int Health; 2017 Jun; 22(6):725-733. PubMed ID: 28342180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
